The significant beat on both EPS and revenue expectations for Q4 indicates a strong financial performance by CytomX Therapeutics, which could lead to positive investor sentiment and a potential increase in stock price in the short term. However, past performance shows that even after beating EPS estimates, the stock price dropped the following day, indicating that market reaction can be unpredictable.